



January, 2011

Dear Valued Baxter Customer:

We regret to inform you that Baxter Healthcare Corporation has decided to discontinue the manufacturing and distribution of Heparin Sodium in 5% Dextrose Injection liquid premix products. As a result, the following product codes will be deleted from all applicable G.P.O. agreements and individual contracts, effective immediately.

The discontinued Heparin Sodium in 5% Dextrose product codes are:

Product Code	NDC	Size	Concentration	Total Amount
2B0807	0338-0549-03	500 mL	40 USP Heparin units/mL	20,000 USP units/500 mL
2B0802	0338-0550-02	250 mL	100 USP Heparin units/mL	25,000 USP units/250 mL
2B0808	0338-0550-03	500 mL	50 USP Heparin units/mL	25,000 USP units/500 mL

However, Baxter carries a different formulation and concentration of premix Heparin (Heparin Sodium and 0.9% Sodium Chloride Injection) as described below. Baxter resumed production of 2B0953 Heparin Sodium and 0.9% Sodium Chloride Injection in December 2010. We will resume production of 2B0944 Heparin Sodium and 0.9% Sodium Chloride Injection in early 2011. All Baxter Heparin Sodium and 0.9% Sodium Chloride Injection products will be manufactured in accordance with the new USP standard and will be differentiated by lot numbers beginning with the letter "N".

Product Code	NDC	Size	Concentration	Total Amount
2B0953	0338-0431-03	500 mL	2 USP Heparin units/mL	1,000 USP units/500 mL
2B0944	0338-0433-04	1,000 mL	2 USP Heparin units/mL	2,000 USP units/1000 mL

For clinical questions, please call the Medical Information Department at 800-933-0303. For other questions, please contact the Baxter Center for Service at 888-229-0001.

Sincerely,

Thomas J. Progar
Vice President
Marketing Strategy and Operations
Medication Delivery U.S. Region
Baxter Healthcare Corporation

Baxter is a registered trademark of Baxter International Inc.